ERBB2 and neoplasm: This deficiency can be resolved by slow deliver formulation via fusing to anti-HER2 IgG or heavy-chain of IgG.55,96 Targeting antiangiogenic agents by antibody is a useful strategy that can be used for other tumor targets via replacement with other antibody specificities/variable domains.